CION Ameerpet
BRCA1 and BRCA2 get spoken of as one thing, and they are not. They carry different risks, at different ages, with different tumour biology — and which one you carry genuinely changes when risk-reducing surgery is recommended.
"BRCA" is used so consistently as a single word that most people assume BRCA1 and BRCA2 are two versions of the same thing. They are not. They sit on different chromosomes, they produce different proteins, and although both proteins work in the same DNA repair pathway, they do different jobs within it.
That difference shows up in the numbers. Lifetime ovarian cancer risk is roughly 40 to 45 per cent for BRCA1 and roughly 15 to 20 per cent for BRCA2 — a gap of more than double. It also shows up in timing: BRCA1-related ovarian cancer tends to appear earlier, while BRCA2-related disease occurs later, often after 50.
The practical consequence is that BRCA1 vs BRCA2 is not a technicality for your records. It shifts the recommended window for risk-reducing surgery by roughly five years, and for a woman deciding when to complete her family that is a genuinely material difference. If you have a result and do not know which gene it names, that is worth finding out.
Different chromosomes, different proteins, both working in homologous recombination DNA repair — but not interchangeably.
Roughly 40-45% lifetime for BRCA1 against roughly 15-20% for BRCA2.
Which changes when risk-reducing surgery is discussed, and therefore how you plan a family around it.
BRCA1 and BRCA2 also tend to produce different kinds of breast cancer. BRCA1-associated breast cancers are more often triple-negative — lacking oestrogen, progesterone and HER2 receptors — while BRCA2-associated breast cancers are more often hormone-receptor-positive. This is one reason a family history of triple-negative breast cancer in a young relative raises the suspicion of BRCA1 specifically. It also matters for treatment, since receptor status determines which systemic therapies apply. The gene shapes the tumour biology, not just the probability. Source: NCCN Genetic/Familial High-Risk Assessment guidelines.
Approximate figures from published cohort data, alongside the practical differences they produce. Individual risk varies with family history and other factors.
| BRCA1 | BRCA2 | |
|---|---|---|
| Lifetime ovarian cancer risk | Roughly 40-45% | Roughly 15-20% |
| Lifetime breast cancer risk | Roughly 60-70% | Roughly 45-55% |
| Typical ovarian onset | Earlier — risk rises from the late 30s and 40s | Later — risk rises meaningfully after about 50 |
| RRSO usually discussed from | About 35-40 | About 40-45 |
| Typical breast tumour biology | More often triple-negative | More often hormone-receptor-positive |
| Male breast cancer risk | Low | Notably increased |
| Other associated cancers | Some increase in pancreatic risk | Pancreatic and prostate cancer more clearly increased |
| Chromosome | 17 | 13 |
*Approximate lifetime estimates from published cohort studies, reflected in NCCN guidance. Figures vary between studies and are modified by family history, age and other factors. They orient a discussion rather than predict an individual outcome.
Beyond the numbers, here is where knowing which gene you carry alters a decision.
This is the single most consequential difference. Risk-reducing salpingo-oophorectomy is generally discussed from around 35 to 40 for BRCA1 carriers, and from around 40 to 45 for BRCA2. The reasoning is straightforward: BRCA2-related ovarian cancer occurs later, so deferring surgery costs less accumulated risk.
Those extra five years matter enormously to a woman in her late thirties deciding whether to try for another child, or weighing surgical menopause against a demanding period of her career. It is not a rounding difference. See risk-reducing surgery.
For a BRCA1 carrier in her mid-thirties, the ovarian discussion is immediate rather than theoretical, because the recommended surgical window is arriving and there is no effective surveillance in the meantime. For a BRCA2 carrier of the same age, there is more room to plan.
This is worth understanding so that the pace of the conversation makes sense. If your BRCA1 result has been followed by a fairly prompt discussion about surgery, that is not alarm — it reflects the age-defined window and the absence of a screening safety net.
BRCA1 families more often show early-onset breast cancer, triple-negative disease and ovarian cancer. BRCA2 families more often show later-onset breast cancer, hormone-receptor-positive disease, male breast cancer, and pancreatic or prostate cancer among male relatives.
This is why a family history should always ask about male relatives and about cancers other than breast and ovarian. A BRCA2 family with mainly male members can look entirely unremarkable if only breast and ovarian cancer are asked about.
Here the difference matters less. Enhanced breast surveillance with annual MRI alongside mammography, starting from around 25 to 30, applies to carriers of both genes, with the exact start age adjusted for family history rather than for which gene is involved.
The tumour biology differs, but the surveillance strategy does not — and this is the pathway where surveillance genuinely works, unlike the ovarian one. See the BRCA breast-ovarian link.
Both BRCA1 and BRCA2 ovarian cancers have impaired homologous recombination repair, which makes them more sensitive to platinum-based chemotherapy and responsive to PARP-inhibitor-class maintenance therapy. That applies to both genes.
For breast cancer the difference in typical receptor status matters more, since it determines which systemic treatments apply. Either way, knowing the gene at diagnosis changes treatment decisions rather than only informing relatives, which is why testing is now offered at diagnosis regardless of family history.
Inheritance is identical: both are autosomal dominant, so each child of a carrier has a fifty per cent chance of inheriting the variant, and both pass through fathers as readily as mothers. Cascade testing works the same way for both.
The residual peritoneal risk after risk-reducing surgery applies equally, as does the absence of effective ovarian surveillance. And for both, a variant is a probability rather than a certainty — most BRCA2 carriers and many BRCA1 carriers never develop ovarian cancer.
"You have BRCA" is not a complete result. These are the details that determine what happens next.
It shifts the recommended surgical window by about five years. If your report does not make it obvious, ask.
A variant of uncertain significance is managed on family history alone, not as a positive result. The distinction is fundamental.
The exact change is what relatives are tested for in cascade testing. It should be recorded and shared with family.
Other genes — RAD51C, RAD51D, BRIP1 and the Lynch genes — also raise ovarian risk. Ask whether they were included.
The gene sets the baseline; your pedigree modifies it. A relative diagnosed young may shift surgical timing earlier.
Carrying a variant is lifelong information and guidance changes. Establish who reviews your plan and how often.
If your report says "variant of uncertain significance", that is not a positive result. It is managed as though nothing had been found, and most are eventually reclassified as benign.
The difference between BRCA1 and BRCA2 is roughly five years in when risk-reducing surgery is recommended. That is a substantial planning difference, not a footnote.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Genetic counselling and BRCA testing are delivered in-house at CION.
A surprising number of people know they carry "a BRCA mutation" without knowing which gene, whether it was definitively pathogenic, or what the specific variant was. That is not carelessness on their part — it reflects how often results are delivered briefly, in writing, without anyone available to work through what they mean.
Your first consultation at CION is free and runs to about 45 minutes, and genetic counselling is delivered in-house. Bring the report itself rather than your recollection of it. The useful work is establishing which gene, whether the finding is pathogenic or of uncertain significance, what the specific variant is for cascade testing, and how your family history modifies the standard timing.
Where cancer does develop, CION delivers medical oncology in-house — chemotherapy and maintenance therapy including PARP-inhibitor-class treatment, across 35+ centres in Telangana and Andhra Pradesh. Risk-reducing salpingo-oophorectomy and any gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there. We state that upfront rather than leaving it to be discovered later.
Counselling, testing and interpretation delivered by one team rather than spread across several referrals.
Which gene, which variant, and whether it is pathogenic are all on the document and all determine what happens next.
Free and unhurried. Long enough to take a proper family history and set the timing conversation in context.
Risk-reducing salpingo-oophorectomy is performed at specialist partner centres and may be billed there.
BRCA1 and BRCA2 account for a large share of hereditary ovarian cancer, but not all of it. Several other genes raise ovarian cancer risk meaningfully, and modern testing usually covers them in the same panel rather than requiring separate tests.
RAD51C, RAD51D and BRIP1 each carry an increased ovarian cancer risk — lower than BRCA1 but sufficient that risk-reducing surgery is generally discussed, typically somewhat later, around 45 to 50. Lynch syndrome genes, principally MLH1, MSH2, MSH6 and PMS2, raise ovarian cancer risk alongside a considerably higher risk of endometrial and bowel cancer, and are managed rather differently. See Lynch syndrome and ovarian cancer.
This matters practically for two reasons. First, if you were tested some years ago for BRCA1 and BRCA2 alone and have a strong family history, an updated panel may now be worthwhile. Second, a negative BRCA result in a family with a striking cancer pattern does not close the question — it may simply mean the responsible gene was not among those tested, and management continues on family history.
Each raises ovarian cancer risk enough that risk-reducing surgery is discussed, typically around 45 to 50.
Raise ovarian risk alongside much higher endometrial and bowel cancer risk, and are managed on a different pathway.
If you were tested years ago for BRCA1 and BRCA2 only, an updated multi-gene panel may be worth discussing.
With a strong family history, no variant found may mean the responsible gene was not tested. Management continues on the pedigree.
For ovarian cancer risk specifically, BRCA1 carries substantially higher risk — roughly 40 to 45 per cent lifetime compared with roughly 15 to 20 per cent for BRCA2 — and the disease tends to occur earlier. BRCA1 also carries somewhat higher breast cancer risk. But worse is not quite the right frame: BRCA2 has a broader associated tumour spectrum, including notably increased male breast cancer risk and more clearly increased pancreatic and prostate cancer risk. What matters practically is that the two are managed on different timetables, so knowing which one you carry genuinely changes your plan.
Yes, and this is the most consequential difference between the two. Risk-reducing salpingo-oophorectomy is generally discussed from around 35 to 40 for BRCA1 carriers and from around 40 to 45 for BRCA2, because BRCA2-related ovarian cancer occurs later so deferring costs less accumulated risk. Those five years matter considerably to a woman deciding whether to try for another child or weighing surgical menopause against a demanding stage of her life. Family history modifies the timing too — a relative diagnosed unusually young may shift the recommendation earlier.
The risk profile differs and so does the typical tumour biology. BRCA1-associated breast cancers are more often triple-negative, meaning they lack oestrogen, progesterone and HER2 receptors, while BRCA2-associated breast cancers are more often hormone-receptor-positive. This is why triple-negative breast cancer in a young relative particularly raises suspicion of BRCA1. For ovarian cancer both are strongly associated with high-grade serous disease. BRCA2 additionally carries notably increased male breast cancer risk and more clearly increased pancreatic and prostate cancer risk.
Ask for a copy of the full laboratory report rather than a summary letter — it will name the gene and the specific variant, usually in a technical notation such as c.68_69delAG. This matters for three reasons: which gene determines the recommended timing of risk-reducing surgery, the specific variant is what relatives are tested for in cascade testing, and the report will state whether the finding was pathogenic or a variant of uncertain significance, which are managed completely differently. If you cannot obtain it, the testing laboratory or the service that arranged the test can help.
Yes, and modern testing usually covers them in the same panel. RAD51C, RAD51D and BRIP1 each raise ovarian cancer risk meaningfully — lower than BRCA1 but enough that risk-reducing surgery is generally discussed, typically around 45 to 50. The Lynch syndrome genes, principally MLH1, MSH2, MSH6 and PMS2, raise ovarian cancer risk alongside considerably higher endometrial and bowel cancer risk and are managed differently. If you were tested some years ago for BRCA1 and BRCA2 alone and have a strong family history, an updated panel may be worth discussing.
Yes, and this is why testing is now offered at diagnosis regardless of family history. Ovarian cancers arising in carriers of either gene have impaired DNA repair, which makes them more sensitive to platinum-based chemotherapy and responsive to PARP-inhibitor-class maintenance therapy — that applies to both BRCA1 and BRCA2. For breast cancer the difference in typical receptor status matters more, since receptor status determines which systemic treatments apply. So the result guides your own treatment as well as informing your relatives about their risk.
Yes — genetic counselling and BRCA and HRD testing are delivered in-house at CION, so the counselling before the test, the test itself, and the interpretation and plan afterwards happen with the same team. The first consultation is free and runs to about 45 minutes, and bringing the full laboratory report rather than a summary letter makes it considerably more productive. CION also delivers medical oncology in-house across more than 35 centres. Risk-reducing salpingo-oophorectomy and any gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there.